Clinical Trials Sponsored by Renova Therapeutics

Total 8155 results

Celldex Therapeutics

Completed

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

Glioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed Glioblastoma

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Entasis Therapeutics

Completed

Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections

Acute Pyelonephritis | Complicated Urinary Tract Infection

Bulgaria
MC2 Therapeutics

Completed

Evaluation of the Vasoconstriction Properties of MC2-01 Cream

Vasoconstriction

France
Atacama Therapeutics

Completed

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Palmar Hyperhidrosis

United States
Centrexion Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

Pain | Chronic Pain | Nociceptive Pain

United States
MC2 Therapeutics

Completed

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

Psoriasis Vulgaris

United States
PTC Therapeutics

Withdrawn

A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia

Aniridia
Heron Therapeutics

Completed

Extended Delivery of Bupivacaine Study in Herniorrhaphy

Analgesia

United States
Cytori Therapeutics

Suspended

Safety and Feasibility of ADRCs Treatment To Patients With Thermal Wounds

Thermal Burn

United States
Celldex Therapeutics

Terminated

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Melanoma

United States
Entasis Therapeutics

Completed

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

Acinetobacter Baumannii-calcoaceticus Complex Infections

United States
Aptevo Therapeutics

Completed

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, Australia
Acorda Therapeutics

Completed

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Poland, Spain
Proteon Therapeutics

Completed

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

Chronic Kidney Disease

United States, Canada
Corcept Therapeutics

Terminated

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

Cushing Syndrome | Hypercortisolism

United States
Effector Therapeutics

Terminated

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Hepatocellular Carcinoma | Triple Negative Breast Cancer

United States
Cyclerion Therapeutics

Completed

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers

Healthy

United States
BioMimetic Therapeutics

Completed

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

Lateral Epicondylitis

United States
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Acorda Therapeutics

Completed

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Idiopathic Parkinson's Disease

United States, Austria, Belgium, Czechia, France, Germany, Hungary, Israel, Netherlands, Poland, Romania, Serbia, Spain, United Kingdom
Acorda Therapeutics

Completed

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes (SPAN-PD™)

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Poland, Spain
Therapeutics, Inc.

Completed

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Elusys Therapeutics

Completed

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

Inhalational Anthrax

United States
PTC Therapeutics

Terminated

PTC299 for Treatment of Advanced Cancer

Advanced Cancer

United States
Proteon Therapeutics

Completed

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Peripheral Artery Disease

United States
Elusys Therapeutics

Completed

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

Inhalational Anthrax

United States
Cyclerion Therapeutics

Completed

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Healthy

United States
Cyclerion Therapeutics

Completed

Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Healthy

United States
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults

Healthy

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

Drug Interaction Potentiation

Canada
Intarcia Therapeutics

Terminated

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Type 2 Diabetes

United States
Amicus Therapeutics

Terminated

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Late-onset Pompe Disease

United States, Canada, Australia, Belgium
Halozyme Therapeutics

Terminated

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC (PRIMAL)

Non-small Cell Lung Cancer

United States
Halozyme Therapeutics

Completed

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) (HALO-117-406)

Type 1 Diabetes Mellitus

United States
Abide Therapeutics

Completed

Central Pain Study for ABX-1431

Multiple Sclerosis | Neuromyelitis Optica Spectrum Disorder | Transverse Myelitis | Longitudinally Extensive Transverse Myelitis

United Kingdom
Corcept Therapeutics

Completed

Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

Cushing's Syndrome

United States
Acorda Therapeutics

Terminated

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine. (MILESTONE℠)

Post-ischemic Stroke

United States, Canada
Balance Therapeutics

Completed

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Idiopathic Hypersomnia | Narcolepsy Without Cataplexy

United States
Halozyme Therapeutics

Completed

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Stage IV Pancreatic Cancer

United States, Russian Federation
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Amicus Therapeutics

Completed

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Fabry Disease

France, Austria, United States, Belgium, Japan, United Kingdom, Denmark, Brazil, Australia, Italy
Amicus Therapeutics

Completed

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Fabry Disease

United States, Italy, Spain, Turkey, Brazil, Canada, United Kingdom, France, Poland, Australia, Egypt, Argentina, Denmark
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Cognition Therapeutics

Completed

Drug Interaction Study of CT1812 in Healthy Volunteers

Healthy Volunteers

United States
Amicus Therapeutics

Completed

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

Fabry Disease

United States, Australia, France, United Kingdom, Brazil, Canada
Amicus Therapeutics

Terminated

Open-Label Phase 3 Long-Term Safety Study of Migalastat (AT1001-041)

Fabry Disease

Australia, United States, Italy, Spain, Belgium, Turkey, Brazil, Argentina, United Kingdom, Denmark, France, Canada, Egypt
Amicus Therapeutics

Completed

Drug-drug Interaction Study

Pompe Disease

France, United States, Canada, United Kingdom
Amicus Therapeutics

Completed

A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

Gaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher Disease

United States
Halozyme Therapeutics

Completed

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

Risk Factors for or a Diagnosis of Osteoporosis

United States

3

Subscribe